Cannabis Compounds Show Promise for Fatty Liver

Interest in cannabis and fatty liver has grown quickly because metabolic dysfunction-associated steatotic liver disease, or MASLD, is now one of the most common chronic liver conditions in the world. Against that backdrop, a March 2026 paper in the British Journal of Pharmacology has attracted attention for a simple reason. It did not just report that two cannabis compounds lowered liver fat in obese mice. It also proposed a fresh mechanism for how those changes happened. The researchers found that cannabidiol, better known as CBD, and cannabigerol, known as CBG, improved glycaemic control, lowered hepatic triglycerides, normalized blood lipids, and appeared to restore key cellular cleanup pathways in the liver. The study was also covered by ScienceDaily, but the paper itself is the stronger source and should be the starting point for any serious discussion of CBD and CBG for fatty liver.

That said, the most responsible way to frame this story is with equal parts interest and caution. This was a preclinical study in mice, not a human trial. It used daily intraperitoneal injections under controlled conditions, not the variable oils, gummies, and tinctures sold in the consumer market. So while the paper adds real scientific weight to the discussion of cannabis and fatty liver, it does not prove that over-the-counter products can reverse fatty liver disease in people. The more useful question is not whether the headline is exciting. It is whether this finding fits with what doctors already know about MASLD, what current treatments can actually do, and where natural treatments for fatty liver might realistically fit if future human trials go well.

What the new study actually found

The new paper, titled Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration, was published on March 5, 2026, in the British Journal of Pharmacology. According to the PubMed abstract, the researchers treated male C57Bl/6 mice with diet-induced obesity and MASLD for 4 weeks using daily intraperitoneal CBD, CBG, or vehicle. Both compounds improved glycaemic control, reduced hepatic triglycerides, and normalized serum lipids without affecting energy expenditure. That last detail matters because it suggests the liver benefits were not merely a side effect of the animals burning more calories overall. Instead, the authors argued that these cannabinoids produced a more targeted metabolic effect inside the liver itself. The ScienceDaily release from March 6 reflected the same central findings and framed the results as showing potential to reverse fatty liver changes in this animal model. 

The study becomes more interesting once the mechanism is examined. The researchers reported increases in hepatic phosphocreatine and creatine, along with higher creatine kinase activity. In practical terms, that points to a stronger cellular energy buffer. The liver is a metabolically expensive tissue, and a liver struggling under fat overload and insulin resistance may benefit if it can better store and rapidly use emergency energy. The authors argued that this phosphocreatine buffering helped the liver adapt without relying on increased fatty acid oxidation. In other words, the compounds did not simply force the liver to burn more fat. They seemed to shift the way hepatocytes handled energy stress. That is a more sophisticated claim than the usual supplement headline, and it is one reason the paper stands out from weaker cannabis and fatty liver stories that offer only a vague promise of anti-inflammatory benefit. 

The second major finding involved lysosomes, which act as the cell’s waste-handling and recycling centers. The paper’s lipidomics and enzyme analyses suggested that CBD and CBG restored cathepsin activity and improved lysosomal lipid degradation. The treatments were also associated with lower levels of triglycerides and ceramides in the liver. Ceramides are important because they are strongly linked to insulin resistance and lipotoxic stress, both of which are central to MASLD progression. If a compound helps reduce ceramide accumulation while improving cellular cleanup, it starts to look less like a simple symptom patch and more like a therapy candidate that could alter disease biology. That does not mean it is ready for patients. It does mean the authors presented a plausible explanation for why these compounds improved liver markers in the animals they studied. 

There was also an important difference between the two cannabinoids. The researchers reported that CBG showed stronger effects on some measures, including body fat mass, insulin sensitivity, total cholesterol, and LDL cholesterol. At the same time, they noted that CBG did not work in a choline-deficient model of steatotic liver disease, which suggests its benefits may depend on intact phospholipid pathways. That is exactly the type of nuance people lose when a headline says cannabis may reverse fatty liver. The real story is narrower and more technical. A specific mouse model improved with carefully administered CBD and CBG, and the mechanism appears linked to energy buffering and lysosomal restoration. That is a real finding, and it deserves attention. 

Why cannabis and fatty liver research is getting so much attention

The reason this paper landed so hard is that MASLD is no small niche condition. Recent epidemiology work suggests that roughly 38% of adults worldwide have MASLD, and the condition ranges from excess fat in the liver to the more dangerous inflammatory form, MASH, which can progress to fibrosis, cirrhosis, liver cancer, and liver failure. The burden is even higher in people with metabolic disease. AASLD guidance stresses that MASH is often linked to obesity, type 2 diabetes, high blood pressure, and high cholesterol. That larger context explains why any credible paper on cannabis and fatty liver gets noticed so quickly. Researchers are not chasing a wellness trend. They are looking for new tools against a huge and growing cardiometabolic disease burden.

Another reason the field is hot is that fatty liver is not just a liver problem. Recent epidemiology and review literature continue to show that MASLD is tied to broader metabolic dysfunction and that cardiovascular disease remains the leading cause of death in this population. That means a therapy that only lowers liver fat without improving insulin resistance or lipid handling may have limited value. The March 2026 CBD and CBG paper is appealing because the reported benefits were broader. The mice did not just show lower hepatic triglycerides. They also showed better glycaemic control and more favorable blood lipid patterns. In that sense, the researchers were speaking the language of modern MASLD care, where the disease is seen as part of a wider metabolic network rather than an isolated liver issue.

The timing also matters because the treatment landscape has changed quickly. In March 2024, the FDA approved Rezdiffra, or resmetirom, for adults with noncirrhotic NASH, now called MASH, with moderate to advanced fibrosis, to be used along with diet and exercise. In August 2025, the FDA also approved Wegovy, which contains semaglutide, to treat adults with MASH and moderate-to-advanced fibrosis. AASLD then updated its guidance in November 2025 to reflect the new semaglutide data and give clinicians practical recommendations for patient selection, comorbidity management, and monitoring. So the story is no longer that doctors have nothing but diet advice. The field now has approved drugs, clearer guidance, and a higher bar for any new therapy trying to break through.

Even so, there is still room for better options. MASLD is common, progressive in some patients, and strongly tied to obesity and diabetes trends that are still moving in the wrong direction globally. That keeps interest high in natural treatments for fatty liver, including compounds that might work through different biological pathways. In theory, a liver-directed therapy that improves cellular energy handling and lysosomal function could complement existing metabolic treatments instead of replacing them. That is why the new paper matters. It does not arrive in an empty therapeutic space, yet it still offers a distinct concept. The study suggests that cannabis and fatty liver research may be moving beyond loose observational talk and into a more mechanistic phase, where the question is not whether cannabis users look different in surveys, but whether specific purified compounds can safely change disease biology in a predictable way.

What still works best right now for fatty liver disease

For all the excitement around CBD and CBG for fatty liver, the strongest evidence in real patients still points in a more familiar direction. Lifestyle treatment remains the foundation of care. NIDDK says that losing at least 3% to 5% of body weight can reduce fat in the liver, while 7% to 10% may be needed to reduce liver inflammation and fibrosis. Physical activity also helps even without major weight loss. That matters because many people hear “fatty liver” and assume the only meaningful option is to wait for a pill. The evidence says otherwise. The basics can be powerful, especially when they are done consistently over time and paired with treatment of diabetes, cholesterol, and blood pressure.

Food quality and energy balance are a major part of that picture. Current guidance emphasizes healthy food choices, sensible portion sizes, and regular physical activity, not extreme cleanses or dramatic detoxes. Those ideas may sound less exciting than a cannabis headline, but they have far better human evidence behind them than most compounds sold as wellness shortcuts. For many people, the most effective natural treatments for fatty liver are not exotic products at all. They are calorie control when needed, less alcohol, better sleep, more movement, and tighter control of related metabolic disease. Patients do not need a miracle narrative to improve their liver. They need an approach that is boring enough to work repeatedly and flexible enough to be maintained.

Medical management has also become more sophisticated. Risk stratification now matters far more than it did a few years ago because the key clinical problem is not simple liver fat alone. It is the possibility of progression to fibrosis and cirrhosis. That is why AASLD emphasizes patient selection, comorbidity management, and monitoring in higher-risk groups, especially people with obesity or type 2 diabetes. Some patients may now be candidates for approved therapies such as resmetirom or semaglutide, depending on fibrosis stage and overall clinical picture. Others may need more aggressive treatment of diabetes or obesity using drugs that also support liver health indirectly. This wider framework is important when discussing cannabis and fatty liver. A promising compound is not entering a vacuum. It has to compete with or complement strategies that already improve clinically meaningful outcomes.

That is also why people should be cautious about replacing established care with self-directed cannabinoid use. A mouse study can be exciting and still not change bedside medicine. The most practical takeaway from the current evidence is that CBD and CBG for fatty liver belong in the research column, while weight reduction, exercise, alcohol moderation, and cardiometabolic treatment belong in the action column. There is nothing glamorous about that split, but it is honest. If future human trials show that cannabinoids improve liver biomarkers, fibrosis risk, or imaging outcomes on top of standard care, then the conversation changes. Until then, any balanced article about cannabis and fatty liver has to say clearly that natural treatments for fatty liver should begin with the interventions that are already proven to help human livers, not with the compounds that are only beginning to show promise in controlled laboratory models.

Where the human evidence still falls short

The biggest gap in this story is not the mechanism. Researchers still lack convincing human trial data. Reviews published in 2024 report promising CBD effects in animal models of steatotic liver disease. However, clinical studies in people have not shown a significant drop in liver fat. One review described an 8-week study in patients with hepatic steatosis. Researchers gave those patients 200, 400, or 800 milligrams of CBD each day. The treatment did not significantly reduce hepatic triglyceride levels. That result does not make the new mouse study irrelevant. It shows that researchers have not yet translated preclinical promise into human benefit. Any honest review on cannabis and fatty liver should keep that point front and center.

There are several possible reasons for that gap. Human disease is messier than mouse disease, and MASLD is not one single pathway. Some patients have more insulin resistance, others have more inflammation, and others are further along the fibrosis spectrum. Formulation may also matter. The new British Journal of Pharmacology paper used controlled dosing and looked at both CBD and CBG, while much of the earlier human conversation centered mainly on CBD. It is entirely possible that CBG proves to be the more important compound, or that a combination therapy works better than one molecule on its own. It is also possible that the liver changes seen in mice depend on a disease model that does not fully capture what happens in diverse human patients. Good science allows for both hope and friction. The new study increases plausibility, but plausibility is not the same as proof.

Safety adds another layer of caution. The FDA continues to state that only one CBD drug product, Epidiolex, is approved in the United States, and it is approved for certain seizure disorders, not fatty liver disease. FDA materials also warn that CBD can cause liver enzyme elevations, with higher doses showing a dose-dependent risk. A 2025 FDA research summary noted that these elevations typically occurred after about two weeks at labeled Epidiolex doses. A 2025 randomized trial in JAMA Internal Medicine also reported liver enzyme elevations in healthy adults using CBD at doses representative of consumer products, with 5.6% experiencing elevations and 4.9% meeting protocol criteria for potential drug-induced liver injury. For someone with fatty liver disease, that is not a trivial issue. 

A compound being studied for liver benefit can still stress the liver under some conditions, especially at higher doses or alongside other medications. That is why the jump from lab paper to supplement shelf is risky. Commercial CBD products vary widely in dose, purity, labeling quality, and contamination risk. The FDA says liver safety data are limited for lower CBD doses and inconsistent in the 200 to 400 milligram per day range, while the JAMA trial warned that unregulated products may not contain the doses users expect. CBG products are even less standardized in many markets. So while the new mouse paper makes CBD and CBG for fatty liver a credible research topic, it does not justify self-prescribing large doses of cannabinoids in the hope of reversing MASLD. 

Conclusion

Researchers now need strong human trials. Those trials must test purified compounds in clearly defined patient groups. They must measure meaningful liver outcomes and track metabolic changes. They must also monitor side effects closely. The new paper points to phosphocreatine buffering and lysosomal restoration. Future trials should test those pathways in human liver tissue when possible. Without that step, this finding remains a promising lab result. It has not yet become a treatment strategy. Researchers must also choose patients carefully. MASLD does not look the same in every person. A younger patient with mild steatosis may respond differently.

Read More: Cannabis-Related Psychosis on the Rise, Study Finds, as Researchers Flag a Vulnerable Group

An older patient with diabetes and fibrosis may need another approach. Some patients may respond better to metabolic therapies. Others may need stronger anti-inflammatory or anti-fibrotic treatment. The new paper showed that CBG failed in a choline-deficient model. That result suggests the biology may shift across disease subtypes. Researchers should use that clue to design sharper trials. Precision will strengthen the science and improve real-world use. Readers should keep the current reality in view. Cannabis and fatty liver remains an active research question. It does not yet offer a proven clinical answer. MASH and MASLD track closely with obesity, diabetes, and abnormal blood lipids. Many people develop no clear symptoms at first.

That pattern makes early risk tracking very important. A new cannabinoid study does not change that fact. People still need steady lifestyle changes and proper medical follow-up. The strongest mouse paper cannot replace those basics. The fairest conclusion stays balanced. This March 2026 paper gives researchers a serious lead. It shows that CBD and CBG may affect liver biology in useful ways. Yet human evidence remains limited. Earlier CBD studies in steatosis produced weak results. Safety questions also remain, especially at higher doses. For now, natural treatments for fatty liver still begin with proven steps. Those steps include weight management, exercise, and lower alcohol intake. Future human trials may expand that list. They have not done so yet.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

A.I. Disclaimer: This article was created with AI assistance and edited by a human for accuracy and clarity.

Read More: Largest Study Yet Suggests Medical Cannabis May Help Combat Cancer